Man Group PLC Protagonist Therapeutics, Inc Transaction History

Man Group PLC

$49.7 Billion
Q2 2025

A detailed history of Man Group PLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Man Group PLC holds 34,013 shares of PTGX stock, worth $2.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,013

Previous 128,606 73.55%

Holding current value

$2.59 Million

Previous $6.22 Million 69.79%

% of portfolio

0.0%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$40.89 - $56.37 $3.87 Million - $5.33 Million	-94,593 Reduced 73.55%	34,013 $1.88 Million
Q1 2025 May 15, 2025	SELL	$35.09 - $59.76 $1.03 Million - $1.75 Million	-29,357 Reduced 18.58%	128,606 $6.22 Million
Q4 2024 Feb 14, 2025	BUY	$38.51 - $48.43 $3.93 Million - $4.95 Million	102,132 Added 182.93%	157,963 $6.1 Million
Q3 2024 Nov 14, 2024	BUY	$33.72 - $47.33 $1.62 Million - $2.28 Million	48,176 Added 629.34%	55,831 $2.51 Million
Q2 2024 Aug 14, 2024	BUY	$24.66 - $34.8 $188,772 - $266,394	7,655 New	7,655 $265,000
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $104,033 - $157,887	14,135 Added 17.68%	94,070 $1.03 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $496,233 - $739,299	63,134 Added 375.78%	79,935 $674,000
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $118,615 - $428,761	16,801 New	16,801 $133,000
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $587,379 - $969,778	-86,126 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$5.99 - $9.1 $515,894 - $783,746	86,126 New	86,126 $579,000

Others Institutions Holding PTGX

# of Institutions

296

Shares Held

67.4M

Call Options Held

290K

Put Options Held

318K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $3.74B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account